Worth Venture Partners’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Worth Venture Partners’s Portfolio MDNA Stock Details MDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,088,938	Closed	-$311K	–	184
2023 Q3	$311K	Hold	1,088,938	–	–	0.18%	94
2023 Q2	$524K	Buy	1,088,938 +35,130	+3%	+$21.7K	0.29%	76
2023 Q1	$685K	Sell	1,053,808 -17,130	-2%	-$10.7K	0.33%	71
2022 Q4	$503K	Buy	1,070,938 +107,137	+11%	+$65.4K	0.3%	78
2022 Q3	$799K	Buy	963,801 +392,312	+69%	+$443K	0.49%	59
2022 Q2	$846K	Hold	571,489	–	–	0.5%	59
2022 Q1	$727K	Buy	571,489 +58,400	+11%	+$90.7K	0.34%	73
2021 Q4	$837K	Buy	513,089 +298,059	+139%	+$618K	0.41%	63
2021 Q3	$595K	Hold	215,030	–	–	0.27%	84
2021 Q2	$647K	Buy	215,030 +17,130	+9%	+$63.4K	0.24%	83
2021 Q1	$807K	Buy	+197,900	New	+$806K	0.39%	64

Other funds holding MDNA

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

NDSI

Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Worth Venture Partners's MDNA Position: Q4 2023 in Review

Worth Venture Partners sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 1,088,938 shares — an estimated $311K sold.

Worth Venture Partners first reported a position in MDNA in Q1 2021 and held it in 11 quarters. The position peaked at $846K in Q2 2022. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

Worth Venture Partners reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
Worth Venture Partners sold 1,088,938 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $311K.
Worth Venture Partners first reported a position in Medicenna Therapeutics Corp. Common Shares in Q1 2021 and held it in 11 quarters.
Worth Venture Partners's Medicenna Therapeutics Corp. Common Shares position peaked at $846K in Q2 2022.
3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Worth Venture Partners's 13F filing for Q4 2023, filed 9 Feb 2024.